ZEOX Zeo ScientifiX, Inc.
Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 1557376 · Fiscal year ends 06/30
Financial factors as of 2025-10-31 (FY2024), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY12.5%
TTM net income YoY-17.3%
TTM EPS YoY-16.2%
Revenue 3-yr CAGR-7.1%
Net income 3-yr CAGR—
Margins
Gross margin82.1%
Operating margin-103.6%
Net margin-106.2%
FCF margin-14.3%
EBITDA margin-102.2%
Returns
ROE—
ROA-348.3%
ROIC (approx.)—
Asset turnover3.28x
Leverage & solvency
Liabilities / assets193.2%
Debt / equity—
Current ratio0.33x
Interest coverage-54.96x
Cash quality & payout
Operating cash flow / net income0.13x
Accruals ratio-303.0%
Payout ratio—
Capex / revenue0.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2027Q12026-09-30 | 2026Q22026-04-30 | 2026Q12026-01-31 | 2024Q4*2025-10-31 | 2025Q42025-09-30 | 2025Q32025-07-31 | 2025Q22025-04-30 | 2025Q12025-01-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $2.06M | $2.58M | $1.45M | $1.65M | $1.39M | $1.31M | $1.15M | $1.09M |
| Cost of revenue | $514,000 | $526,000 | $281,000 | $256,000 | $284,000 | $228,000 | $256,000 | $191,000 |
| Gross profit | $1.55M | $2.06M | $1.17M | $1.40M | $1.10M | $1.08M | $893,000 | $899,000 |
| R&D expense | $16 | $31,000 | $19,000 | — | $20 | — | $42,000 | $6,000 |
| SG&A expense | $3.81M | $2.57M | $2.04M | $2.07M | $2.03M | $3.15M | $2.29M | $2.15M |
| Operating income | -$2.26M | -$512,000 | -$878,000 | -$668,000 | -$926,000 | -$2.07M | -$1.39M | -$1.25M |
| Interest expense | $9,000 | $11,000 | $10,000 | $32,000 | $22,000 | $23,000 | $21,000 | $22,000 |
| Net income | -$2.21M | -$145,000 | -$852,000 | -$815,000 | -$963,000 | -$2.07M | -$1.39M | -$1.24M |
| EBITDA | -$2.24M | -$493,000 | -$859,000 | -$648,000 | -$906,000 | -$2.05M | -$1.38M | -$1.24M |
| EPS (basic) | -0.28 | -0.02 | -0.12 | — | -0.15 | -0.32 | -0.22 | -0.20 |
| EPS (diluted) | -0.28 | -0.02 | -0.12 | — | -0.15 | -0.32 | -0.22 | -0.20 |
| Weighted avg. shares (diluted) | 7.84M | 7.76M | 7.02M | — | 6.47M | 6.41M | 6.34M | 6.34M |
| Balance sheet | ||||||||
| Cash & equivalents | $1.24M | $1.85M | $1.03M | $221,000 | $261,000 | $314,000 | $542,000 | $720,000 |
| Receivables | $331,000 | $276,000 | $63,000 | $35,000 | — | — | $11,000 | $6,000 |
| Inventory | $934,000 | $686,000 | $502,000 | $423,000 | — | $258,000 | $235,000 | $245,000 |
| Current assets | $2.79M | $3.27M | $2.01M | $958,000 | — | $1.06M | $865,000 | $1.09M |
| PP&E, net | $574,000 | $609,000 | $564,000 | $569,000 | — | $589,000 | $570,000 | $460,000 |
| Total assets | $3.42M | $3.89M | $2.57M | $1.53M | — | $1.65M | $1.44M | $1.55M |
| Current liabilities | $4.52M | $3.11M | $2.89M | $2.87M | — | $3.88M | $3.45M | $3.35M |
| Short-term debt | — | $247,000 | $245,000 | $243,000 | — | $698,000 | $692,000 | $686,000 |
| Total liabilities | $4.58M | $3.17M | $2.95M | $2.95M | — | $3.97M | $3.54M | $3.35M |
| Shareholders' equity | -$1.14M | $712,000 | -$383,000 | -$1.42M | -$2.20M | -$2.31M | -$2.10M | -$1.80M |
| Shares outstanding | 7.84M | 7.79M | 7.61M | 6.75M | — | 6.50M | 6.34M | 6.34M |
| Cash flow statement | ||||||||
| Operating cash flow | -$768,000 | -$138,000 | -$471,000 | -$383,000 | -$128,000 | -$257,000 | -$143,000 | $65,000 |
| Capital expenditure | — | $64,000 | $14,000 | $0 | — | — | — | — |
| Free cash flow | — | -$202,000 | -$485,000 | -$383,000 | — | — | — | — |
| Investing cash flow | — | $312,000 | -$14,000 | $0 | — | — | — | — |
| Financing cash flow | -$257,000 | $642,000 | $1.29M | $290,000 | $247,000 | $52,000 | -$35,000 | -$2,000 |
| Depreciation & amortization | $21,000 | $19,000 | $19,000 | $20,000 | $20,000 | $19,000 | $16,000 | $18,000 |
| Stock-based compensation | $478,000 | $590,000 | $592,000 | $756,000 | $852,000 | $1.75M | $1.10M | $1.09M |
Free plan shows the latest 8 periods; Pro shows all 60 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.